iTeos to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 13, 2021
May 06 2021 - 04:01PM
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today announced that it will host a
conference call and live webcast at 4:30 p.m. ET on Thursday, May
13th, 2021 to report its first quarter 2021 financial results and
provide a corporate update.
Conference Call
Dial-in numbers: (833) 607-1661 (US/Canada) or (914) 987-7874
(International); Conference ID: 6160559
Webcast
A live audio webcast will be accessible from the Events page of
the Company’s IR website at
https://investors.iteostherapeutics.com/news-and-events/events. A
replay will be available on the Company’s website approximately two
hours after completion of the event and for 30 days following the
call
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of cancer
immunology and immunosuppressive pathways to design novel product
candidates with the potential to fully restore the immune response
against cancer. The Company’s innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes. The initial antibody product candidate,
EOS-448, is a high affinity, potent, anti-TIGIT antibody with a
functional Fc domain, designed to enhance the anti-tumor response
through a multifaceted immune modulatory mechanism. An open-label
Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer
patients with advanced solid tumors with preliminary data
indicating clinical activity as a monotherapy and a favorable
tolerability profile. The Company is also advancing inupadenant, a
next-generation adenosine A2A receptor antagonist tailored to
overcome cancer immunosuppression. iTeos is conducting an
open-label multi-arm Phase 1/2a clinical trial of inupadenant in
adult cancer patients with advanced solid tumors. Preliminary
results indicate encouraging single-agent activity in the dose
escalation portion of the trial. iTeos Therapeutics is
headquartered in Cambridge, MA with a research center in Gosselies,
Belgium.
For further information, please contact:
Investor Contact:Ryan BakeriTeos Therapeutics,
Inc.Ryan.Baker@iteostherapeutics.com
Media Contacts:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Feb 2024 to Mar 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Mar 2023 to Mar 2024